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Methods:	 HI-	titers	 against	 the	 pandemic	 virus	 were	measured	 in	 maternal	 blood	
samples	obtained	at	birth,	3-	9	months	after	exposure,	and	 linked	with	 information	
about	 pregnancy,	 influenza	 and	 vaccination	 from	 national	 registries	 and	 a	 cohort	
questionnaire.
Results:	 Among	 1821	 pregnant	 women	 included,	 43.7%	 were	 unvaccinated	 and	
19.3%	of	these	had	ILI.	HI-	titers	were	low	(geometric	mean	titer	(GMT)	11.3)	in	the	
unvaccinated	women	with	ILI.	Higher	HI-	titers	(GMT	37.8)	were	measured	in	the	vac-







More	 severe	 ILI	or	 longer	duration	of	 illness	was	associated	with	higher	HI-	titers.	
Most	unvaccinated	pregnant	women	with	ILI	had	low	HI-	titers,	probably	due	to	mod-
erate	illness	and	HI-	titer	waning	between	exposure	and	sampling.
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1  | INTRODUC TION
During	 the	 2009	 influenza	 A(H1N1)	 pandemic,	 pregnant	 women	
were	at	increased	risk	of	hospitalization	and	death	due	to	severe	in-
fluenza	 infection.1-3	Following	the	first	reports	on	this	association,	





1,	 2009,	 to	 December	 31,	 2009,	 peaking	 in	 early	 November.4,5	 A	
vaccination	 campaign	 with	 the	 AS03-	adjuvanted	 A(H1N1)pdm09	
vaccine	 (Pandemrix)	 started	 19th	 October.	 The	 vaccine	 was	 rec-
ommended	 to	 pregnant	women	 in	 their	 second	 or	 third	 trimester	
and	to	groups	at	high	risk	of	severe	influenza.6	It	was	mandatory	to	
report	pandemic	vaccination	 to	 the	national	 immunisation	 register	
(SYSVAK).4,5	 Approximately	 54%	 of	 pregnant	 Norwegian	 women	
were	vaccinated.4
In	 contrast,	 among	 46	000	 pregnancies	 in	 Norway	 during	 the	
pandemic,	only	516	cases	of	 laboratory-	confirmed	 influenza	 infec-
tion	were	registered.	Due	to	limited	laboratory	capacity	during	the	
pandemic,	 testing	 of	 patients	 with	 severe	 illness	 was	 prioritized.	
Furthermore,	only	8.9%	of	women	who	gave	birth	in	2009	or	2010	
were	 diagnosed	with	 influenza	 by	 a	 physician.4	However,	 national	
influenza	surveillance	data	indicated	a	clinical	attack	rate	of	approx-
imately	30%	in	the	Norwegian	population.5




























also	 studied	whether	HI-	titers	were	 associated	with	 self-	reported	
ILI	symptoms,	severity	or	duration	of	ILI,	in	this	cohort	of	pregnant	
women.
2  | MATERIAL S AND METHODS
2.1 | The NorFlu cohort
Pregnant	 women	 with	 their	 last	 menstrual	 date	 between	 June	 1,	
2009,	and	December	31,	2009,	were	eligible	for	recruitment.	Women	







participants	 completed	 a	 questionnaire	 on	 influenza	 and	 vaccina-










2.2 | Hemagglutination inhibition (HI) assay
Maternal	serum	samples	were	tested	in	HI	assays	with	the	pandemic	
vaccine	virus	NYMC	X-	179A,	in	twofold	dilutions	starting	at	1:10.24 
The	 HI-	titer	 was	 defined	 as	 the	 reciprocal	 of	 the	 highest	 serum	





Women	 registered	 with	 one	 dose	 of	 the	 pandemic	 vaccine	 in	
SYSVAK	(date	of	vaccination	registered),	or	self-	reported	pandemic	
vaccination	 in	 the	 questionnaire	 (month	 and	 year	 of	 vaccination),	
were	defined	as	vaccinated.
2.4 | Influenza and ILI categories
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in	MSIS	during	the	main	pandemic	period.	Women	who	solely	self-	






if	 any	 of	 the	 following	 data	 were	missing:	 biological	 samples,	 HI-	
titer	measurements,	questionnaire	data	or	MBRN	records	(Figure	1).	
Women	were	also	excluded	if	their	pregnancy	started	after	the	pan-
demic	period,	 if	 their	start-	date	was	unknown,	or	 if	 they	were	not	
pregnant	when	they	were	vaccinated	or	had	ILI.	Women	who	self-	
reported	vaccination	had	to	be	pregnant	by	October	19,	2009,	when	
the	 vaccination	 campaign	 started.	 For	 women	 with	 self-	reported	


























very	 ill,”	 “quite	 ill,”	and	“very	 ill.”	Duration	of	 ILI	was	based	on	the	






Linear	 regression	 analysis	was	 used	 to	 estimate	waning	 of	HI-	
titers	 among	 unvaccinated	 (n	=	154)	 women	 with	 ILI	 and	 vacci-
nated	women	without	 ILI	 (n	=	909).17	Women	who	had	been	both	



















Women included in the study
n = 1821
Excluded women 
No biological sample: n = 793
No HI data: n = 43
No questionnaire data: n = 389
No MBRNa data: n = 3
Pregnant after pandemic: n = 7
Pregnancy start unknown: n = 15





















Women in the NorFlu
pregnancy cohort
n = 3201
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difference	 between	 the	 estimated	 rates	 of	 decline	 among	women	





ILI,	 possibly	 due	 to	 the	 high	HI-	titers	 induced	by	 the	 vaccine.30,31 
Analyses	of	HI-	titers	 in	the	different	 ILI	categories	were	therefore	
restricted	 to	 unvaccinated	 women	 (n	=	796).	 The	 association	 be-
tween	HI-	titers	and	symptoms,	severity	and	duration	were	studied	





for	 women	with	 or	 without	 ILI	 giving	 birth	 ≥210-	≤280	days	 after	
the	pandemic	 (>60%	of	the	women)	and	for	medically	attended	vs	
self-	report	women	giving	birth	≥180-	≤270	days	after	the	ILI	episode	




bies	were	 born	 between	March	 and	 September	 2010,	 and	 88.3%	
of	the	questionnaires	were	completed	either	before	birth	or	in	the	
month	of	giving	birth.	Among	the	included	women,	56.3%	(n	=	1025)	
were	 vaccinated	with	 the	 pandemic	 vaccine.	 The	majority	 of	 vac-














had	medically	 attended	 influenza	 and	 57.8%	 had	 self-	reported	 ILI	
(Table	1).	Unvaccinated	women	had	significantly	more	ILI	than	vacci-
nated	women	(19.3%	vs	11.3%,	respectively).
3.1 | Estimation of HI- titer waning
Figure	2	 shows	 the	 estimated	waning	 of	HI-	titers	 over	 time	 since	
exposure	 for	 vaccinated	 women	 with	 no	 ILI	 (n	=	909)	 and	 unvac-
cinated	 women	 with	 ILI	 (n	=	154).	 The	 mean	 time	 since	 exposure	
was	 194	days	 (range	 66-	289)	 for	 vaccinated	 cases	 and	233	 (range	
135-	307)	for	ILI	cases.	HI-	titers	were	significantly	higher	in	the	vac-
cinated	 women	 than	 in	 women	 with	 ILI	 (P	<	0.001).	 The	 HI-	titers	








Since	 medically	 attended	 influenza	 possibly	 represents	 cases	
more	 likely	due	 to	 influenza	virus	 and/or	more	 severe	 illness	 than	




The	estimated	HI-	titer	half-	life	 for	 the	medically	 attended	women	
was	250	days,	slightly	longer	than	for	all	women	with	ILI.
3.2 | HI- titers in the unvaccinated women
We	 observed	 low	 HI-	titers	 (GMT	 11.3)	 among	 the	 unvaccinated	
women	with	ILI;	however,	they	had	significantly	higher	HI-	titers	than	
women	with	no	 ILI	 (GMT	6.5,	P	<	0.0001;	Figure	3A).	Several	of	 the	
unvaccinated	 women	 with	 laboratory-	confirmed	 influenza	 also	 had	
low	titers	(11.1%	with	HI	<	10	and	33.3%	with	HI	<	20).	80.1%	of	the	
women	with	 no	 ILI	 had	HI	<	10,	 compared	 to	 50.0%	of	 the	women	
with	ILI	(P	<	0.001).	Conversely,	35%	of	women	with	ILI	had	HI-	titers	
≥20	 compared	 to	 9.6%	 of	 women	 without	 ILI	 (P	<	0.001).	 Women	
with	 medically	 attended	 influenza	 had	 significantly	 higher	 HI-	titers	
(P	=	0.001,	GMT	14.8)	 than	women	with	 self-	reported	 ILI	 (GMT	9.2;	












3.3 | HI- titers and self- reported symptoms, 
severity and duration of ILI in unvaccinated women
The	frequency	of	self-	reported	symptoms	in	unvaccinated	women	with	
ILI	is	listed	in	Table	2.	Women	who	reported	fever,	cough,	sore	throat,	
shortness	 of	 breath	 or	 chest	 pain	 had	 significantly	 higher	 HI-	titers	












Women reporting the 
symptom, n (%)
Geometric mean HI- titer (95% CI)





If symptom not 
reported
Fever 128	(83.1) 12.6	(10.4,	15.1) 6.9	(5.3,	9.0) 0.005
Headache 117	(76.0) 11.7	(9.7,	14.2) 10.2	(7.2,	14.5) 0.31
Sore	throat 114	(74.0) 13.0	(10.6,	15.9) 7.7	(6.0,	9.9) 0.003
Stuffy	nose/
runny nose
108	(70.1) 12.7	(10.3,	15.6) 8.7	(6.8,	11.2) 0.06
Cough 103	(66.9) 13.7	(11.1,	17.0) 7.7	(6.2,	9.6) 0.0007
Muscle	pain 94	(61.0) 12.2	(9.9,	15.1) 10.1	(7.7,	13.2) 0.13
Joint	pains 86	(55.8) 10.8	(8.8,	13.1) 12.1	(9.1,	16.1) 0.96
Shortness	of	
breath
73	(47.4) 13.8	(10.6,	18.0) 9.5	(7.8,	11.6) 0.04
Vomiting,	
diarrhea
46	(29.9) 12.5	(9.3,16.9) 10.9	(8.9,	13.3) 0.30
Chest	pain 21	(13.6) 17.5	(11.4,	27.0) 10.6	(8.9,	12.6) 0.01








     |  7TUNHEIM ET al.
Most	 of	 the	 unvaccinated	 women	 with	 ILI	 felt	 “quite	 ill”	
(67.4%).	Women	who	were	 “very	 ill”	 had	 significantly	 higher	HI-	
titers	 (GMT	24.8)	compared	to	women	who	reported	 less	severe	
ILI	 (either	 “not	 very	 ill”	 GMT	 8.4,	 P	=	0.002	 or	 “quite	 ill”	 GMT	
12.2,	P	=	0.03;	Figure	5A).	The	proportion	of	women	with	an	HI-	
titer	 ≥20	 increased	 from	 18.8%	 to	 69.2%	with	 increasing	 sever-
ity	 (P-	values	<	0.05	 for	 “very	 ill”	 vs	either	 “not	very	 ill”	 or	 “quite	
ill”).	 Most	 women	 (64.9%)	 reported	 an	 ILI	 duration	 of	 3-	5	days.	
HI-	titers	 were	 significantly	 higher	 in	 women	 who	 reported	 ILI	
for	more	 than	5	days	 (GMT	22.3)	 than	 in	women	with	 a	 shorter	
duration	of	 illness	 (GMT	8.6,	P	=	0.04	vs	0-	2	days	 and	GMT	9.5,	
P	=	0.001	vs	3-	5	days;	Figure	5B).	Again,	there	was	a	significantly	
higher	proportion	(P	<	0.001)	of	women	with	HI-	titers	≥20	(62.5%)	
among	women	with	more	 than	5	days	of	 ILI	 than	among	women	
with	 shorter	 durations.	 A	 subanalysis	 of	 only	 the	 laboratory-	







influenza	A(H1N1)	 pandemic,	HI-	titers	 against	 the	 pandemic	 virus	
were	 measured	 in	 maternal	 blood	 samples	 collected	 at	 delivery,	
3-	9	months	after	exposure	to	pandemic	infection	or	vaccination.	We	
found	 that	HI-	titers	were	higher	 after	 vaccination	with	 the	AS03-	
adjuvanted	vaccine	 than	after	 ILI.	HI-	titers	waned	over	 time,	both	










found	 that	 the	 AS03-	adjuvanted	 pandemic	 vaccine	 had	 induced	
























8  |     TUNHEIM ET al.







confirmed	 influenza.	 Low	HI-	titers	 after	 PCR-	confirmed	pandemic	
influenza	 have	 also	 been	 described	 previously.33-35	 An	 HI-	titer	
threshold	of	20	has	been	suggested	to	provide	sufficient	serological	









vaccination	 with	 an	 adjuvanted	 pandemic	 vaccine	 or	 after	 mild/
moderate	 ILI.	Moreover,	 the	estimated	HI-	titer	half-	lives	 indicated	
that	 the	39-	day	difference	 in	 the	mean	 time	since	exposure	could	
not	explain	the	observed	titer	difference	between	these	groups.	HI-	




our	 finding,	 in	 the	previously	mentioned	US	study	of	40	pregnant	
women,	waning	was	 not	 significantly	 different	 after	 immunization	
with	a	non-	adjuvanted	vaccine	or	infection.17
Prior	to	the	2009	pandemic,	pregnant	women	in	Norway	were	
not	 routinely	 advised	 to	 be	 vaccinated	 against	 seasonal	 influenza	
and	 only	 the	 pandemic	 vaccine	 was	 recommended	 for	 pregnant	
women	during	the	pandemic.4	In	the	present	study,	the	percentage	
of	self-	reported	vaccinations	was	comparable	to	the	percentage	of	







if	 ILI	 is	 caused	 by	 the	 influenza	 virus,	 as	 opposed	 to	 other	 infec-
tious	agents.	However,	the	cohort	was	population-	based	and	most	
women	reported	moderate	illness.	Thus,	few	of	the	pregnant	women	
were	 subjected	 to	 laboratory	 testing.4,37	This	 is	 also	 in	 line	with	a	








restricting	 the	analyses	 to	 ILI	occurring	during	 the	main	pandemic	
peak,	 the	 likelihood	 that	 ILI	 was	 indeed	 caused	 by	 the	 pandemic	
virus was increased.38	According	 to	national	 surveillance	data,	 the	
pandemic	virus	was	by	 far	 the	dominating	respiratory	virus	at	 this	
time.38
As	can	be	expected,	medically	attended	influenza	was	associated	
with	 higher	 HI-	titers	 as	 compared	 to	 self-	reported	 ILI.	 This	 could	





implying	 that	 they	were	 infected	with	 influenza.	 Furthermore,	 ac-
cording	to	the	questionnaire	data,	74.0%	of	the	women	with	ILI	met	
the	 CDC	 definition	 of	 ILI,	 supporting	 our	 classification	 of	women	
without	 laboratory-	confirmed	 influenza,	 as	 pandemic	 cases.	 Some	




Information	 on	 symptoms	 was	 self-	reported	 in	 questionnaires	
listing	classical	influenza	symptoms,39-42	with	fever	reported	as	the	
most	common	symptom.	Typical	influenza	symptoms	(fever,	cough,	
sore	 throat,	 shortness	 of	 breath,	 and	 chest	 pain)	were	 associated	
with	higher	HI-	titers	which	probably	reflects	that	women	reporting	















The	 strength	of	 this	 study	was	 that	 it	was	conducted	within	a	








A	 limitation	 of	 our	 study	 was	 that	 recruitment	 of	 the	 study	
participants	was	not	feasible	until	after	the	pandemic	peak,	hence	
pre-	pandemic	 or	 pre-	pregnancy	 samples	 could	 not	 be	 obtained	












To	 conclude,	 in	 this	 population-	based	 cohort	 of	women	who	
were	 pregnant	 during	 the	 2009	 influenza	 A(H1N1)	 pandemic,	
we	 found	 that	 vaccination	 with	 the	 AS03-	adjuvanted	 pandemic	
vaccine	induced	much	higher	HI-	titers	than	ILI.	50%	of	the	vacci-
nated	women	had	HI-	titers	≥20	even	8	months	after	vaccination.	
Despite	 the	 observed	 HI-	titer	 differences	 between	 vaccinated	
women	 and	women	with	 ILI,	 the	 estimated	HI-	titer	 waning	was	
similar.	Knowledge	on	 the	 longevity	of	maternal	 antibodies	 is	 of	











Bærum	Hospital	 and	Haukeland	Hospital	 for	 recruitment	 of	 preg-
nant	women	and	blood	collection,	and	all	the	members	of	the	NorFlu	
study	 group	 at	 the	 Norwegian	 Institute	 of	 Public	 Health	 and	 the	
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